Objectives: Lung cancer is the leading cause of cancer-related mortality in both men and women worldwide. Small cell lung cancer (SCLC) represents 15-20 % of all lung cancers. The aim of this study was to evaluate the clinical features of small cell lung cancer (NSCLC) cases that were diagnosed in our clinic.
Introduction
Lung cancer is the most common malignancy and the leading cause of cancer-related mortality in both men and women worldwide (1) . Small cell lung cancer (SCLC) represents 15-20 % of all lung cancers and SCLL almost always occurs in someone with a history of cigarette smoking (2) . It is a high-grade neuroendocrine carcinoma of the lung and named for its distinct histologic features, it is characterized by its aggressive nature, typically presenting with a small lung nodule, bulky hilar/mediastinal adenopathy, and evidence of extrathoracic metastatic spread (3) . Common metastasis sites are liver, adrenal, bone marrow, bone and brain. Prognosis is related to number of metastatic sites involved.
SCLC is clinically categorized into two stages, as either limited or extensive disease according to the Veterans Administration Lung Study Group system (2). The TNM staging system is also recommended (4). Relapse is frequent within months and overall survival remains poor. For limited-stage SCLC, the median survival time is 18 to 24 months, with 2-year and 5-year survival rates of approximately 40% and 20% to 26%, respectively. For extensive-stage SCLC, the median survival time is 9 to 10 months, with less than 10% survival at 2 years and virtually no survival at 5 years (1,2,5)
The aim of this study is to evaluate the clinical features and treatment results of unselected patient population with SCLC that were diagnosed in our clinic.
Materials and Methods
We analyzed 64 patients in the retrospective study, who had been diagnosed as SCLC in our clinic. The files of patients were reviewed to identify patients and the data's including demographic characteristics, history and physical examination, laboratory values, radiological findings, diagnostic procedures, treatment modalities, response and survival. The diagnosis of SCLC was confirmed by the histologic or cytologic findings in all cases. Staging was done by computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and brain, and radionuclide bone scanning. The definition used for staging was; Limited stage (LS) defined as limited to ipsilateral hemithorax and extensive stage (ES) disease as spreading beyond the ipsilateral hemithorax including both contralateral hilar or supraclavicular adenopathy and malignant pleural or pericardial effusion.
Chemoradiotheraphy, only chemotheraphy, radiotheraphy modalities were recorded. Chemotherapy was given in a 21-day cycle in the sequential arm. The patients received six cycles of chemotherapy. Each three-or four-week cycle consisted of 80 mg of cisplatin per square meter of body-surface area on day 1 and 100 mg of etoposide per square meter on days 1, 2, and 3. Cranial radiotherapy was administered for cranial metastasis. For sequentional chemoradiotheraphy, the same chemotherapy was applied and added curative radiotherapy after completion of chemotherapy.
Overall survival (OS) was measured from the date of histologic or cytologic confirmation to the date of death from any cause or most recent follow-up.
Statistical Analysis
Statistical Evaluation Statistical analyses were performed with SPSS (statistical package for social sciences) software. Categorical data are expressed as numbers with frequencies and continuous data are expressed as medians with interquartile range (IQR). For survival analysis, Kaplan-Meier method was used from the day of diagnosis.
Results
Sixty four patients were enrolled during the study period. The group included 59 men (92.1 %) and 5 women (7.8 %); the median age was 57.5 ±8.1. Patients were current smokers with the median consumption of 50.3 pack-years. The performance of the patients was not very poor, 40,6% of Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS) was 1 and 20,3 % of ECOG-PS was 0. The characteristics of the patients and the clinicopathological and management data are reported in Table I .
The most frequent admission symptoms were chest pain, cough and weight loss 42%, 39,1% and 26,6%, respectively ( Table 2 ). In laboratory findings; mean hemoglobin level was 11,3± 2,7 , mean sedimentation rate was 55,3± 12 mm/hr. The most common radiologic finding on chest X-ray was increased hilar density and mediastinal widening .On Thorax CT hilar solid mass and hilar lympadenopathies were common. 
The diagnosis was established by histopathologic examination of biopsy specimens obtained by various means, in which bronchoscopy was the sole means of diagnosis in 92,2% of the patients. The diagnostic procedures are shown in Table 3 .The stages of SCLC were limited disease in 26(29,7) and extensive disease in 38 (59,3%) patients. The liver (29,7%) was the most common metastatic side, that was followed by bone and brain.
The chemotherapy procedure was applied to sixty (93,7 %) patients ,chemoradiotherapy for 2 (3.1%) patients and radiotherapy for 20 (31.2%) patients. Myelosuppression was common in chemotherapy procedures. Anemia was much more frequent and followed by leukopenia and nausea. Esophagitis was the most common toxicity of radiotherapy. The second line chemotherapy was required in 10 patients. The most common treatment discontinuation cause was progression (12.5 %) and poor performance (7.8%).
Five (7,8%) patient had complete response (CR). forty nine (76,5%) patients had partial response. Ten (15,6%) patients did not turn up after treatment. The median survival was 309 days, 210 days and 270 days for LS, ES and overall patients, respectively. 
Discussion
Our data describe a patient population as seen in daily clinical setting over a period of 2,5 years. Of the 64 patients 38 were ES and 26 were LS. Treatment was generally well tolerated. In patients with small cell lung cancer, the median survival was 309 days, 210 days and 270 days for LS, ES and overall.
The median age was 57.5 ±8.1 years which is similar in the literature (6) (7) (8) . Smoking is the most important cause of lung cancer. Previous studies reported strongest association between smoking and lung cancer and denoted that up to 98 % of the patients have smoking history (9-11). We found that all patients were current smoker. Patients with lung cancer often suffer from multiple symptoms which could be features of local disease (shortness of breath, chest pain, cough, hemoptysis), locally advanced disease (hoarseness of voice, facial swelling, dysphagia), extrathoracic spread (seizures, focal neurological deficits, bone pain) and weight loss and anorexia (which are imagined to be possible signs of sub-clinical systemic disease); (12, 13) this was also observed in our study, as weight loss was strongly associated with extensive disease and chest pain and cough was associated with limited disease.
Fiberoptic bronchoscopy was effective diagnostic procedure especially in lung cancer. In our study population, bronchoscopy was diagnostic in 92,2% of the patients which was consistent with the previous studies (4, 15, 14) . In extensive stage small cell lung cancer, main metastatic sites were liver, brain, bone, adrenal glands and pleura. The frequency of metastases and the number of metastatic sites in our study were similar as in patient populations of several international randomized trials (15) (16) (17) .
In SCLC various chemotherapies have been investigated, but no one regimen has shown superior mortality benefit. Generally, platinum-based, doublet chemotherapy has become the standard of care. Cisplatin plus etoposide is a recommended regimen, also can be substituted for cisplatin when toxicity is intolerable (2) . We used cisplatin plus etoposide, only two patient were treated with carboplatin plus etoposide. Even though SCLC is chemosensitive, a significant proportion of patients are unable to tolerate chemotherapy. This is due to the fact that most patients present with extensive disease and a poor performance status, associated with severe debilitating symptoms related to the primary tumor, as well as its metastatic manifestations.
The median duration of survival of patients with limited and extensive disease was 309 days and 210 days, respectively, which was comparable to previous studies (18) .This results are similar with Tatlısöz et al. that reported from our country. However our survival values are lower than Sonmez et all's study (19) . This may be higher rate of extensive disease in our study population.
Conclusion
In conclusion, demographic and clinical features of our study were similar with previous studies. Because of the high rate of extended disease median survival for overall patients were lower than studies in literature.
Early diagnosis in limited disease may be adjust the value of survival in patients with SCLC.
